Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Hematol Oncol ; 21(1): 1-9, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12605417

RESUMO

A population-based multicentre study for childhood acute lymphoblastic leukemia (ALL) was conducted in Hong Kong from 1993 to 1997. One hundred and forty-five newly diagnosed ALL patients were treated by the HKALL 93 protocol. Patients were stratified into three risk groups according to age, presenting white cell count, immunophenotyping and cytogenetic study. The patients received the same induction and early and late intensification at week 5 and week 20. Fifty-eight standard risk (SR) patients received regular intrathecal methotrexate as CNS preventive therapy, while 49 intermediate risk (IR) patients received high dose intravenous methotrexate and regular intrathecal methotrexate. Thirty-eight high risk (HR) patients were treated with prophylactic cranial irradiation and an additional intensification block at week 35. The induction remission rate was 97.2% with 2% induction death. Two patients died during first complete remission. Relapse occurred in 20.7, 42.9 and 42.1% of SR, IR and HR patients respectively. By multivariate logistic regression, age> or =10 years and white cell count> or =100 x 10(9)/l were the two significant variables accounting for mortality. The 5-year overall and event-free survival of the whole group was 81.3 and 62.6% respectively. According to risk groups, the event-free survival was 79, 49 and 61% for SR, IR and HR patients respectively, while the overall survival was 96, 73 and 68% for SR, IR and HR patients respectively. In conclusion, the treatment protocol had low treatment-related mortality but was associated with a rather high relapse rate, especially in IR patients. Salvage therapy achieved sustained second remission in some patients. More intensive treatment especially a late intensification is required to improve the outcome.


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Fatores Etários , Neoplasias do Sistema Nervoso Central/prevenção & controle , Criança , Pré-Escolar , Intervalo Livre de Doença , Feminino , Hong Kong , Humanos , Imunofenotipagem , Lactente , Modelos Logísticos , Masculino , Metotrexato/farmacologia , Prognóstico , Recidiva , Análise de Regressão , Terapia de Salvação , Fatores de Tempo
2.
Arch Dis Child ; 86(5): 344-7, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11970927

RESUMO

AIMS: To study the prevalence and severity of liver diseases of transfusion dependent thalassaemia major patients, and correlate the histological and biochemical changes of iron overload in liver with the peripheral blood markers. METHOD: Liver biopsy was performed to assess the histological changes and liver iron content (LIC). RESULTS: One hundred patients were evaluated (median age 11.7 years, range 1.5-27). A total of 81 liver biopsies were performed in 73 patients; 43 samples were analysed for LIC. Grade 3-4 haemosiderosis and hepatic fibrosis was found in 44% and 30% of patients respectively; both were significantly associated with higher serum ferritin, liver enzymes, and LIC. Very high LIC (>15 mg/g dry weight) was present in 16.3% of patients. CONCLUSION: Severe haemosiderosis and hepatic fibrosis were common in patients with thalassaemia major despite the use of chelation therapy. Liver biopsy provided information on fibrosis and LIC which could not be accurately predicted from peripheral blood markers.


Assuntos
Cirrose Hepática/etiologia , Talassemia beta/patologia , Adolescente , Adulto , Alanina Transaminase/sangue , Análise de Variância , Biópsia/métodos , Criança , Pré-Escolar , Desferroxamina/uso terapêutico , Feminino , Ferritinas/sangue , Humanos , Quelantes de Ferro/uso terapêutico , Cirrose Hepática/enzimologia , Cirrose Hepática/patologia , Masculino , Estudos Retrospectivos , Talassemia beta/tratamento farmacológico
3.
Bone Marrow Transplant ; 29(2): 101-5, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11850702

RESUMO

From August 1992 to August 1999, 44 patients received allogeneic haematopoietic stem cell transplantation in a single institution. The donors were HLA-identical siblings except for one who was a phenotypically matched father. Thirty-eight patients received bone marrow stem cells and the others received peripheral blood stem cells or umbilical cord blood (UCB). The mean age at transplant was 10.7+/-5.1 years, ranging from 1.8 to 21 years. Patients received busulphan (16 mg/kg) and cyclophosphamide (150 to 200 mg/kg) as conditioning, and antithymocyte globulin was given to 42 patients to prevent graft rejection. All had engraftment except a patient who received a UCB transplant. Four patients died from early treatment-related mortality, and one died from interstitial pneumonitis 3 months after transplant. Two patients developed secondary graft rejection and both received a second transplant. Thirty-eight patients survived and all except one were transfusion independent. The 5-year overall and event-free survival rates were 86% and 82%, respectively. By multivariate stepwise Cox proportional hazard analyses, severe veno-occlusive disease (VOD) of liver and Pesaro class 3 features were the significant factors associated with survival. Patients aged more than 11 years were more inclined to develop VOD. In conclusion, haematopoietic stem cell transplantation should be performed early if an HLA identical sibling is available.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Talassemia beta/terapia , Adolescente , Adulto , Fatores Etários , Criança , Pré-Escolar , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Hepatopatia Veno-Oclusiva/etiologia , Hepatopatia Veno-Oclusiva/mortalidade , Teste de Histocompatibilidade , Homozigoto , Hong Kong/epidemiologia , Humanos , Lactente , Masculino , Prognóstico , Fatores de Risco , Irmãos , Transplante Homólogo , Resultado do Tratamento , Talassemia beta/complicações , Talassemia beta/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA